DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent... EP3 is a target that associates with increased risk of various vascular diseases.
- Mechanism
- Curator reviewed
DG041 is an antagonist of the EP3 receptor for prostaglandins E2 - a receptor involved in peripheral artery disease (PAD). DG041 produces concentration-dependent inhibition of one of the platelet activation pathways and reduces platelet aggregation without increasing bleeding time. Studies have shown that DG041 dramatically inhibits platelet activation mediated through VASP as well as platelet aggregation. DG041 also reduced levels of another indicator of platelet activation, p-selectin, and several markers of inflammation -- c-reactive protein (CRP), monocyte chemotactic protein 1 (MCP1), and soluble intracellular adhesion molecule (sICAM) -- in a dose-dependent manner.
- Primary indication
- Investigated for use/treatment in peripheral vascular disease.Curator reviewed
- Code names
- DG041
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with DG041, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account